The 2 analysts offering 12-month price forecasts for ARS Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 5.00 and a low estimate of 3.00. The median estimate represents a +2.04% increase from the last price of 3.92.
The current consensus among 3 polled investment analysts is to Hold stock in ARS Pharmaceuticals Inc. This rating has held steady since September, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.20
Reporting Date Nov 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.